Biogen Names Priya Singhal as Executive Vice President, Head of Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Biogen (BIIB) gains ahead of lecanemab PDUFA
January 6, 2023 7:05 AM ESTBiogen (NASDAQ: BIIB) is gaining 1% in pre-open trade ahead of lecanemab's accelerated approval PDUFA today.
After the close, analysts at RBC Capital noted that Eisai's patient assistance hotline for Leqembi/lecanemab just became active suggesting "increased likelihood an approval."
... MoreRBC Capital on Biogen (BIIB): 'a very favorable stock setup'
January 5, 2023 4:11 PM ESTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Sometime between late this morning and now, Eisai's patient assistance hotline for Leqembi/lecanemab just became active, whereas for the last several weeks the phone number (which we obtained via Google search) had not been... More
Biogen's (BIIB) accelerated PDUFA lecanemab approval the likely outcome claim analysts
January 5, 2023 11:50 AM ESTBiogen's (NASDAQ: BIIB) lecanemab's accelerated approval PDUFA is slated for Friday, January 6, and analysts have been weighing in with their view heading into the date.
Jefferies analyst Michael Yee, who has a Buy rating and a $350 price target on Biogen shares, said in a note to clients that the "consensus assumes clean approval, which is reasonable though mostly... More
